Attitudes Towards Prophylactic Colectomy in Hereditary Non-polyposis Colorectal Cancer (HNPCC) Patients
NCT ID: NCT00582452
Last Updated: 2009-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
16 participants
OBSERVATIONAL
2004-11-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
FAMILY_BASED
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Affected patients who are at high risk for metachronous colorectal tumors due to mutation status.
Telephone survey
Telephone survey
1
Unaffected patients who are at high risk for developing colon cancer based on family history and/or mutation status.
Telephone survey
Telephone survey
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telephone survey
Telephone survey
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* meet Amsterdam I or Amsterdam II criteria that spell out the family and personal cancer history characteristics associated with HNPCC
* are considered at sufficiently high risk by their CRC specialty physician that prophylactic colectomy may be presented as an option (excluding FAP).
Amsterdam I Criteria
1. At least three relatives with a colorectal cancer and the following criteria:
* One should be a first degree relative of the other two
* At least two successive generations should be affected
* At least one colorectal cancer should be diagnosed before the age of 50
* Familial Adenomatous Polyposis (FAP) should be excluded in the colorectal cancer case(s), if any
Amsterdam II Criteria (also known as Revised Amsterdam Criteria
2. At least three relatives with an HNPCC-associated cancer (colorectal cancer, cancer of the endometrium, small bowel, ureter, or renal pelvis) \*:
* One should be a first degree relative of the other two
* At least two successive generations should be affected
* At least one relative should be diagnosed before age 50
* FAP should be excluded in the colorectal cancer case(s), if any \*NOTE: ovarian cancer will also be considered an HNPCCassociated cancer as per Lynch et al (NEJM 2003)
Exclusion Criteria
* under the age of 18
* are unable to give meaningful informed consent due to physical, psychiatric or cognitive disability
* are from a family affected by FAP
* have already undergone subtotal colectomy or total proctocolectomy
* are in active treatment and/or less than six months post-surgery for cancer.
* Have undergone genetic counseling and testing for HNPCC at MSKCC
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Memorial Sloan Kettering Cancer Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karen Hurley, PhD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI CA101511
Identifier Type: -
Identifier Source: secondary_id
CA109236
Identifier Type: -
Identifier Source: secondary_id
04-127
Identifier Type: -
Identifier Source: org_study_id